• Is mesothelin a key to tackling solid tumors? Some biotech companies are betting that it is

    15 days ago - By STAT

    On Target is a recurring feature from STAT that dives deep into the most promising drug targets in oncology. This column is adapted from a new STAT report , “Targeting cancer: the new frontier of immunotherapy and precision oncology.”
    Scientists working to produce immunotherapies for solid tumor cancers have spent decades searching for biological targets that can help them distinguish between healthy cells and cancerous ones. Finding such biomarkers is critical to developing treatments that can kill the cancer without also killing the patient.
    Read more ...